Latest Share Chat

Futura Medical Share News (FUM)

Futura Medical Information

Buy FUM Shares
Add FUM to Watchlist
Add FUM to Alert

Share Price Information for Futura Medical (FUM)

Share Price is delayed by 15 minutes

Get Live Data

Share Price: 36.30

Bid: 36.30

Ask: 37.00

Change: 0.525 (1.45%)

Spread: 0.70 (1.928%)

Open: 35.80

High: 36.30

Low: 35.80

Prev. Close: 36.125

Last checked at -

AIM WINNERS & LOSERS: Futura Medical up on EU medical device clearance

Fri, 19th Mar 2021 11:20

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Friday.

----------

AIM - WINNERS

----------

Futura Medical, more than doubles to 38.8 pence, 12-month range 7.5p-47.4p. The pharmaceutical company says the European Union is to certificate its MED3000 as a Class 2B approved medical device. Once the certificate is received, Futura's topical gel formulation MED3000 will become the first pan-European topical treatment for erectile dysfunction available without the need for a doctor's prescription.

----------

ReNeuron Group, up 11% at 120.30p, 12-month range 70p-179p. The cell-based therapeutics developer unveils new collaborations and data findings on its exosome technology platform. Its exosome technology is being explored by pharmaceutical, biotechnology and academic partners as a new delivery vehicle for third-party therapeutic agents targeting the brain and other parts of the body. The company is developing its lead exosome candidate from its proprietary CTX neural stem cell line. If the data collected from the new collaborations is positive, ReNeuron believes it could seek out-licensing deals in next six months.

----------

Primorus Investments, up 13% at 5.19p, 12-month range 1.53p-5.19p. Chair Rupert Labrum buys 1.0 million shares at 4.49p each, GBP44,900, on Thursday and now holds a 21% stake.

----------

AIM - LOSERS

----------

B90 Holdings, down 38% at 20.5p, 12-month range 4.5p-38.81p. The online marketing company comments on recent share price volatility after being restored to trading on Wednesday. B90 confirms it is not in possession of any unpublished price sensitive information, and there are no further updates to Wednesday's announcement or in the context of its business generally.

----------

IDOX, down 17% at 59.24p, 12-month range 27.1p-79p. The management software provider confirms Dye & Durham does not intend to make an offer to buy the company, and it agrees to sell its Grants Consultancy business to SilverTree Equity for EUR8.1 million

----------

By Arvind Bhunjun; arvindbhunjun@alliancenews.com

More News

30 Jun 2010 08:56

Futura Medical Signs Development Deal With GlaxoSmithKline

LONDON (Dow Jones)--Pharmaceutical company Futura Medical PLC (FUM.LN) Tuesday said it signed a deal with GlaxoSmithKline PLC's (GSK.LN) cosumer healthcare unit to develop a painkiller. GlaxoSmithKline will be responsible for the clinical and regulatory development of Futura's TR100 and Futura w

12 May 2010 12:36

Small caps round-up: Aurelian, Cineworld, Greggs...

Eastern Europe focused oil and gas explorer and producer Aurelian today reconfirmed "steady" progress against all targets set out in October's strategy document. "We are on track to spud our first two high impact wells in line with our milestones; in June we commence the drilling of the first multi

2 Mar 2010 12:38

Small caps round-up: Share, Jetion Solar, Futura Medical...

Share, parent company of retail stockbroker The Share Centre, lifted profits last year to £2.35m from £1.46m on turnover of £14.1m, up from £12m. There was a significant increase in retail investor activity - especially online with deal volumes up by 75% on 2008, Share said. The interim dividend is

16 Dec 2009 08:43

Futura a step closer to TPR100 deal

Consumer healthcare product developer Futura Medical is in talks with a major pharmaceutical company on a licensing deal for its pain relief product, TPR100. The company interested in licensing TPR100 is the same one with which Futura announced an evaluation agreement in July 2009. Futura has rece

12 Nov 2009 14:32

Small caps round-up: Syntopix, Atlantic Coal, Brady...

Drug developer Syntopix shares rallied as it reported positive phase 2 results for its lead dermatological compound SYN0126, for the treatment of acneic skin. Following the results, Syntopix has decided to focus its development efforts around three specific core compounds: SYN0126, SYN1113 and SYN

10 Nov 2009 09:22

Production changes in line for Futura condom

Futura Medical said a number of potential improvements to the production process of its ‘erectogenic’ condom have been identified by Durex condom maker SSL International. The proposed changes to the manufacturing process at SSL’s manufacturing facility in India have the potential to improve product

23 Sep 2009 13:10

Small caps round-up: Lifeline Scientific, Autologic, Bond...

The market liked Lifeline Scientific's maiden interim operating profit of $73,000 versus last year's loss of $3.1m, as the sale of 11 new LifePort kidney transporters helped revenue jump 123% to $7.75m. 'Trading was in-line with management's expectations during the first half and the board is confi

20 Jul 2009 08:35

Small caps round-up: Abbeycrest, Synchronica, Futura...

Jewellery maker Abbeycrest said it is performing in line with expectations as it undergoes a turnaround plan. The unbranded jewellery business is delivering much improved results on a significantly reduced turnover, the firm said. The brands division is making good progress with its higher margin b

10 Jun 2009 08:27

Small caps round-up: Intelligent Environments, LPA Group, Mobile Streams...

Banking software firm Intelligent Environments said trading in the current year to date has been robust. The group said it has experienced strong demand from new and existing customers to launch platforms to attract and retain retail deposits online. "Our strategy to develop a long term recurring r

13 May 2009 09:20

Small caps round-up: H&T Group, China Medical, Fyffes...

Pawnbroker H&T Group said it has traded "significantly" ahead of expectations for the year to date. It also said it was positive about prospects for the current year but remains conscious of the current difficult economic climate. "The principal reason for the strong performance is the sustained go

Latest Share Chat

Futura Medical Share News (FUM)

Share Price Information for Futura Medical (FUM)

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

AIM WINNERS & LOSERS: Futura Medical up on EU medical device clearance

Login to your account

Quickpicks are a member only feature

Login to your account